Molecules

Sestamibi

Target Myocardial perfusionClass Lipophilic cationic technetium complexOther names MIBI, methoxyisobutylisonitrile

1ongoing trials
1radiolabelled forms
1approved products
8,026publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C36H66N6O6Tc
Molar mass (g/mol)
777.9
Exact mass (Da)
777.4106
H-bond donors
0
H-bond acceptors
12
Rotatable bonds
12
Heavy atoms
49
InChIKey
KNMLZCYLMYOYBD-KTTJZPQESA-N
PubChem record
CID 449763 ↗
IUPAC name
hexakis(1-isocyano-2-methoxy-2-methylpropane);technetium-99
SMILES
CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.CC(C)(C[N+]#[C-])OC.[99Tc]

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[⁹⁹ᵐTc]Tc-sestamibi Syntheses and QC ↗Imaging777.91Phase 3SPECT perfusion (sestamibi, tetrofosmin, thallium) US EU FR JP

Ongoing trials · 1Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
Myocardial perfusion tracersNCT02324387 · OtherNo phaseActive, not recruitingM.D. Anderson Cancer Center1
Other trials listing it among the interventions (comparator, associated scan) · 3
Myocardial perfusion tracersNCT07439133 · Ischemic heart diseasePhase 3RecruitingSinotau Pharmaceutical Group1
Myocardial perfusion tracersNCT01899833 · Ischemic heart diseasePhase 2Not yet recruitingCell>Point LLC1
Myocardial perfusion tracersNCT05042687 · OtherNo phaseRecruitingM.D. Anderson Cancer Center1

PublicationsAll publications in PubMed ↗

8,026 publications in PubMed for the query below; the most recent:

sestamibi[tiab] OR MIBI[tiab]

  1. Bilateral multifocal water-clear cell parathyroid adenoma: A case report with literature review Radiol Case Rep, 2026
  2. Cautious clinical interpretation of preoperative Tc-(99m)-Sestamibi localization scan among chronic kidney disease and transplanted patients Surg Pract Sci, 2026
  3. Assessing the effectiveness of (18)F-Fluorocholine PET-CT as the leading imaging technique compared to (99m)Tc-Sestamibi scans and ultrasonography for diagnosing hyperparathyroidism Appl Radiat Isot, 2026
  4. Multimodality imaging localization of a giant functional parathyroid adenoma in a young fitness trainer with delayed recognition of hypercalcemia: A case report Radiol Case Rep, 2026
  5. Reversing the Reverse: Nitrate-Enhanced Tc-99m MIBI MPS Unmasking Microvascular Dysfunction in Takayasu Arteritis Clin Nucl Med, 2026
  6. The diagnostic utility of multiphase CT (4D CT) in localizing parathyroid adenomas following negative or discordant 99mTc-sestamibi SPECT/CT and ultrasound imaging Br J Radiol, 2026
  7. Incidental Detection of Enterogastric Bile Reflux in 99m Tc-Sestamibi Myocardial Perfusion Imaging Clin Nucl Med, 2026
  8. Primary Hyperparathyroidism-Induced Acute Pancreatitis: Case Report and Systematic Review Pancreas, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

Sestamibi. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/sestamibi/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.